The going annualized interest rate paid by those who borrowed shares in the social networking company was anywhere from 10% to 40% on the amount borrowed on Friday, compared with 0.25% to 0.5% for the typical big-company stock, according to RobertSloan, managing partner of S3 Partners, a New York firm that advises hedge funds on counterparty risk and financing of trade.
Afinitor delayed disease progression in patients with kidney cancer by a modest three months in a 416-patient trial led by Robert Motzer, an oncologist at Memorial Sloan-Kettering Cancer Center.
In June oncologist Robert Motzer of New York's Memorial Sloan-Kettering Cancer Center reported that SU11248 dramatically shrank tumors in 33% of 63 kidney cancer patients tested (including Judy Norris) and halted tumor growth in another 37%.